RNA modification, such as N6-methyladenosine (m6A), 5-methylcytosine (m5C), N4-acetylcytidine (ac4C), pseudouridine (Ψ), and N1-methyladenosine (m1A), have come to be recognized as essential regulators in cancer biology. These modifications influence various aspects of tumorigenesis, tumor progression, and therapeutic response. In urological tumors—such as renal cell carcinoma, prostate cancer, and bladder cancer—these RNA modifications play pivotal roles in modulating gene expression and cellular pathways associated with tumorigenesis, cancer development and progression. Recent studies have shown that dysregulation of RNA modifications can affect the stability, translation, and function of oncogenes and tumor suppressor genes, establishing them potential biomarkers and therapeutic targets in urological malignancies.

This Research Topic aims to explore the intricate roles and mechanisms of RNA modifications in the diagnosis, treatment, and prognosis of urological tumors. We seek to uncover how different RNA modifications contribute to the molecular landscape of these cancers and how they can be leveraged for clinical applications. By compiling recent advancements, this collection will highlight novel insights into the involvement of RNA modifications in tumor biology, offering new avenues for personalized medicine. Specifically, the goal is to address gaps in understanding the molecular mechanisms through which RNA modifications influence urological cancer outcomes and to identify potential therapeutic targets and biomarkers for diagnosis and prognosis within these cancers.

We invite submissions that cover a wide range of topics related to RNA modifications in urological cancers. We welcome original research articles, reviews, mini-reviews, and perspective pieces that contribute to the understanding of RNA modifications in urological oncology. Possible topics includes, but are not limited to:

• Mechanistic studies of RNA modifications in renal cell carcinoma, prostate cancer, and bladder cancer.

• The role of m6A, m1A, m5C, and other RNA modifications in the regulation of oncogenes and tumor suppressor genes.

• Clinical studies investigating RNA modifications as biomarkers for early diagnosis and prognosis.

• Therapeutic strategies targeting RNA modifications, including small molecules and CRISPR-based approaches.

• Bioinformatics and high-throughput sequencing analyses elucidating the landscape of RNA modifications in urological tumors, requiring validation through independent clinical or patient cohorts, or through biological validation in vitro or in vivo.

Submit your idea

Impact

Frontiers in Genetics

Participating Journals

Submit your idea

Impact